The stock of GSK Plc ADR (NYSE:GSK) last traded at $34.44, down -0.09% from the previous session.
Data from the available sources indicates that GSK Plc ADR (NYSE:GSK) is covered by 22 analysts. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $62.61 and a low of $30.03, we find $40.59. Given the previous closing price of $34.47, this indicates a potential upside of 17.75 percent. GSK stock price is now -4.64% away from the 50-day moving average and -3.03% away from the 200-day moving average. The market capitalization of the company currently stands at $69.85B.
Elon Musk just Triggered a BOOM in These Stocks
Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"
Click Here to Download the FREE Report.
Sponsored
In total, 9 analysts have assigned it a hold rating, and 9 have given it a buy rating. Brokers who have rated the stock have averaged $41.98 as their price target over the next twelve months.
A total of 0.00% of the company’s stock is owned by insiders.
With an opening price of $34.42 on Thursday morning, GSK Plc ADR (NYSE: GSK) set off the trading day. During the past 12 months, GSK Plc ADR has had a low of $32.15 and a high of $39.74. As of last week, the company has a debt-to-equity ratio of 1.59, a current ratio of 0.95, and a quick ratio of 0.70. According to the stock market information, the enterprise value for the company is $88.94B, which is based on a 9.47 price-to-earnings ratio, a 1.97 price-to-earnings-growth ratio, and a beta of 0.65. The fifty day moving average price for GSK is $36.11 and a two-hundred day moving average price translates $35.51 for the stock.
The latest earnings results from GSK Plc ADR (NYSE: GSK) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.28, beating analysts’ expectations of $1.14 by 0.14. This compares to $5.52 EPS in the same period last year. The net profit margin was 20.47% and return on equity was 56.81% for GSK. The company reported revenue of $10.31 billion for the quarter, compared to $9.22 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.85 percent. For the current quarter, analysts expect GSK to generate $9.17B in revenue.
GSK Plc ADR(GSK) Company Profile
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
